High insulin with a normal HbA1c is a clinically significant finding that many people — and some clinicians — can overlook. HbA1c measures average blood glucose over two to three months, and a normal result (below 42 mmol/mol on NHS and NICE criteria) confirms glucose has not been persistently raised. However, it does not confirm that the body's insulin system is working efficiently. Elevated insulin alongside a normal HbA1c often signals early insulin resistance, where the pancreas is compensating to keep blood sugar in check. Recognising this pattern early creates a valuable window for preventive action before more serious metabolic conditions develop.

What It Means to Have High Insulin With a Normal HbA1c

High insulin with a normal HbA1c suggests the pancreas is compensating for insulin resistance, keeping blood glucose within normal limits while working harder than it should — an early metabolic warning sign.

Receiving a result showing high insulin levels alongside a normal HbA1c can be confusing, particularly when you may have been told your blood sugar is within a healthy range. HbA1c measures the average blood glucose concentration over the preceding two to three months by assessing the proportion of haemoglobin that has glucose attached to it. In the UK, a normal HbA1c is below 42 mmol/mol, in line with NHS and NICE diagnostic thresholds (NICE NG28-aligned criteria). A normal result suggests that blood glucose has not been persistently elevated — but this does not necessarily mean that the body's insulin system is functioning optimally.

It is important to note that HbA1c is not reliable in certain situations. Results may be misleading in people with anaemia, haemoglobin variants or haemoglobinopathies (such as sickle cell trait or thalassaemia), chronic kidney disease, pregnancy, or those who have recently had a blood transfusion or received erythropoietin therapy. In these circumstances, clinicians may use fasting plasma glucose, an oral glucose tolerance test (OGTT), or fructosamine instead. If any of these conditions apply to you, discuss with your GP which test is most appropriate.

Insulin is a hormone produced by the beta cells of the pancreas. Its primary role is to facilitate the uptake of glucose into cells, particularly in muscle, fat, and liver tissue. When cells become less responsive to insulin — a state known as insulin resistance — the pancreas compensates by producing more insulin to achieve the same blood glucose-lowering effect. In the early stages, this compensatory mechanism can be highly effective, keeping blood glucose and HbA1c within normal limits while insulin levels quietly rise.

This pattern — elevated fasting or post-meal insulin with a normal HbA1c — is clinically significant. It suggests the body is working harder than it should to maintain normal glucose levels and may be an early indicator of metabolic risk, warranting further assessment even in the absence of a diabetes diagnosis. Understanding this distinction is important for both patients and clinicians, as it opens a window for preventive intervention before more serious metabolic conditions develop.

Understanding Insulin Resistance and Early Metabolic Changes

Insulin resistance develops gradually; during the compensatory phase, HbA1c remains normal while fasting insulin rises, and this reversible stage is the optimal point for lifestyle intervention to prevent type 2 diabetes.

Insulin resistance is a condition in which the body's cells do not respond normally to insulin signalling. Rather than a sudden switch, it develops gradually over months or years, often driven by a combination of lifestyle, genetic, and hormonal factors. In the early phase, the pancreas is able to compensate by secreting progressively larger amounts of insulin — sometimes referred to as hyperinsulinaemic compensation. During this window, blood glucose and therefore HbA1c may remain entirely normal.

At a cellular level, insulin resistance involves impaired signalling through the insulin receptor pathway, reducing the movement of glucose transporters to the cell surface in muscle and fat tissue, so less glucose is taken up from the bloodstream. The liver may also continue to produce glucose despite elevated insulin levels — a phenomenon known as hepatic insulin resistance — further straining the system. A common visible sign of significant hyperinsulinaemia is acanthosis nigricans — a darkening and thickening of the skin, typically in the neck creases, armpits, or groin — which may prompt clinical investigation.

Over time, if insulin resistance is not addressed, the beta cells of the pancreas can become exhausted. Insulin secretion begins to decline, and blood glucose levels start to rise — first as impaired fasting glucose or impaired glucose tolerance, and eventually as type 2 diabetes. Importantly, the stage of high insulin with normal HbA1c represents a critical and potentially reversible point in this progression, and evidence consistently shows that lifestyle intervention at this stage can meaningfully reduce risk (NICE PH38).

Metabolic changes during this phase may also include:

• Rising triglyceride levels

• Falling HDL cholesterol

• Increasing blood pressure

• Central (abdominal) weight gain

These features collectively form part of what is recognised as metabolic syndrome. Using International Diabetes Federation (IDF) criteria — widely applied in UK practice — metabolic syndrome is defined by central obesity (waist circumference ≥94 cm in European men, ≥80 cm in European women, with lower thresholds for South Asian, Chinese, and Japanese populations) plus two or more of: raised triglycerides, reduced HDL cholesterol, raised blood pressure, or raised fasting glucose. Metabolic syndrome is strongly associated with cardiovascular disease and type 2 diabetes. Further information is available on the NHS metabolic syndrome page.

Causes of Raised Insulin Levels When Blood Sugar Appears Normal

The most common cause of raised insulin with normal HbA1c is insulin resistance, driven by central obesity, inactivity, PCOS, NAFLD, certain medicines, sleep disorders, or chronic stress.

There are several reasons why insulin levels may be elevated despite a normal HbA1c. The most common underlying cause is insulin resistance, which can itself be driven by a range of factors. Understanding the root cause is essential for guiding appropriate management.

Common causes include:

• Excess body weight and central obesity: Adipose tissue, particularly visceral fat around the abdomen, releases inflammatory cytokines and free fatty acids that are associated with impaired insulin signalling in peripheral tissues.

• Physical inactivity: Skeletal muscle is the primary site of insulin-mediated glucose disposal. Sedentary behaviour is associated with significantly reduced muscle insulin sensitivity.

• Polycystic ovary syndrome (PCOS): A common hormonal condition in women of reproductive age, PCOS is strongly associated with insulin resistance independent of body weight. Raised insulin levels can worsen androgen excess and disrupt ovulation (NICE NG88).

• Non-alcoholic fatty liver disease (NAFLD): Excess fat in the liver is associated with hepatic insulin resistance and is both a cause and consequence of the condition (NICE NG49).

• Certain medicines: Corticosteroids and some atypical antipsychotics — particularly olanzapine and clozapine — are associated with worsening insulin resistance and raised fasting insulin (MHRA/BNF). Among antihypertensives, thiazide diuretics and non-selective beta-blockers have the most evidence for adverse metabolic effects; ACE inhibitors and angiotensin receptor blockers (ARBs) are generally considered metabolically neutral or potentially beneficial. Do not stop or change any prescribed medicine without first speaking to your GP or pharmacist.

• Sleep disorders: Obstructive sleep apnoea and chronic sleep deprivation are independently associated with raised fasting insulin (NICE NG202).

• Chronic stress: Elevated cortisol from prolonged psychological or physiological stress is associated with antagonism of insulin action.

Rarer endocrine conditions — including Cushing's syndrome (excess cortisol), acromegaly (excess growth hormone), severe hypothyroidism, and lipodystrophy — can also cause significant insulin resistance and should be considered if other features are present. A clinician can assess whether specialist investigation is warranted.

Less commonly, a rare condition called an insulinoma — a tumour of the pancreatic beta cells — can cause excess insulin secretion. This typically presents with hypoglycaemia (low blood sugar) rather than normal blood glucose. If you experience symptoms of hypoglycaemia — such as sweating, tremor, palpitations, confusion, or loss of consciousness — seek urgent medical assessment. Insulinoma is usually identified through specialist investigation.

A thorough clinical assessment is always required to identify the underlying cause in any individual.

How UK Clinicians Investigate and Interpret These Results

Fasting insulin is not routinely measured on the NHS; when requested, it is interpreted alongside fasting glucose using HOMA-IR, though this is a research tool and results must be contextualised by a clinician.

In UK clinical practice, fasting insulin is not routinely measured as part of standard NHS blood panels. HbA1c, fasting glucose, and lipid profiles are far more commonly used to assess metabolic health. However, fasting insulin may be requested in specific clinical contexts — for example, when investigating PCOS, unexplained weight gain, or suspected metabolic syndrome — often by a GP or specialist such as an endocrinologist or gynaecologist.

When interpreting a fasting insulin result, clinicians may consider it alongside fasting glucose to calculate the HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) score: fasting insulin (mU/L) × fasting glucose (mmol/L) ÷ 22.5. It is important to note that HOMA-IR is primarily a research and adjunctive clinical tool — it is not a standardised NHS diagnostic test. Reference ranges vary between laboratories and populations, and insulin assay methodology differs between centres, meaning results are not directly comparable across laboratories. A value above approximately 2.0–2.5 is sometimes used as a research indicator of insulin resistance, but this threshold is not universally validated and should be interpreted by a clinician with knowledge of the local assay used.

Where HbA1c is unreliable (see above), or where more detailed glucose metabolism assessment is needed — particularly in PCOS — clinicians may use a fasting plasma glucose or an oral glucose tolerance test (OGTT). NICE NG88 recommends considering an OGTT at diagnosis of PCOS and periodic rescreening for glucose abnormalities, given the elevated metabolic risk in this group.

NICE public health guidance on type 2 diabetes prevention (PH38) and the associated NHS Diabetes Prevention Programme (NHS DPP) support assessment of metabolic risk factors in at-risk individuals. Clinicians may also request:

• Fasting lipid profile (to identify dyslipidaemia)

• Liver function tests and, where NAFLD is suspected, non-invasive fibrosis assessment using tools such as FIB-4 or the Enhanced Liver Fibrosis (ELF) test before or alongside liver ultrasound, in line with NICE NG49

• Blood pressure measurement

• Waist circumference (a practical marker of central adiposity)

• Full blood count and thyroid function (to exclude other contributing conditions)

A single fasting insulin result should always be interpreted in clinical context. Factors such as recent food intake, acute stress, and laboratory methodology can all influence the result. Patients are encouraged to discuss their results directly with their GP rather than drawing conclusions independently.

Health Risks Associated With Chronic High Insulin Levels

Persistently elevated insulin is associated with cardiovascular disease, progression to type 2 diabetes, NAFLD, hormonal disruption, and emerging links to cognitive decline — even before HbA1c becomes abnormal.

Persistently elevated insulin levels — even in the presence of a normal HbA1c — are associated with a range of longer-term health risks. This is partly because high insulin itself has direct biological effects beyond glucose regulation, and partly because it reflects an underlying state of metabolic dysfunction that, if uncorrected, tends to progress.

Cardiovascular disease is among the most significant concerns. Chronic hyperinsulinaemia is associated with arterial smooth muscle proliferation, sodium retention (which may contribute to raised blood pressure), and dyslipidaemia — particularly elevated triglycerides and reduced HDL cholesterol. These changes are associated with accelerated atherosclerosis and increased risk of heart attack and stroke, even before blood glucose becomes abnormal. Much of this evidence is observational and confounded by shared risk factors; a causal relationship has not been definitively established in all cases. CVD risk should be assessed using validated tools such as QRISK in UK primary care, in line with current NICE lipid modification guidance.

Progression to type 2 diabetes is a well-established association. Evidence suggests that individuals with insulin resistance and compensatory hyperinsulinaemia have a substantially elevated risk of developing type 2 diabetes over a five to ten year period, particularly if lifestyle factors are not addressed (Diabetes UK; NICE PH38). The NHS Diabetes Prevention Programme targets individuals at high risk — typically identified by HbA1c or fasting glucose thresholds — but the window of raised insulin with normal HbA1c may represent an even earlier opportunity for intervention.

Additional health risks associated with chronic high insulin include:

• Non-alcoholic fatty liver disease (NAFLD) and its potential progression to non-alcoholic steatohepatitis (NASH) and liver fibrosis

• Hormonal disruption, including worsening of PCOS symptoms and potential effects on fertility

• Increased cancer risk: some observational research suggests associations between hyperinsulinaemia and colorectal, breast, and endometrial cancers, as insulin can act as a growth factor; however, causality has not been established and this evidence requires cautious interpretation

• Cognitive decline: emerging observational evidence links insulin resistance with increased dementia risk (Alzheimer's Society); this area of research is ongoing

• Renal and microvascular risk within the context of metabolic syndrome, particularly as glucose regulation deteriorates over time

These associations underline why identifying and addressing high insulin early — even with a normal HbA1c — is clinically meaningful.

Next Steps and Management Options Available on the NHS

Discuss raised insulin results with your GP, who can arrange further investigations and refer you to NHS services; lifestyle modification is the primary treatment, with metformin considered off-label for insulin resistance in PCOS.

If you have been found to have raised insulin levels alongside a normal HbA1c, the most important first step is to discuss the result with your GP. They can contextualise the finding within your broader health picture, arrange any additional investigations, and refer you to appropriate services if needed. Seek a GP appointment promptly if you also have symptoms such as unexplained weight gain, fatigue, irregular periods, acanthosis nigricans, or other features of metabolic syndrome. As noted above, if you experience symptoms of hypoglycaemia (sweating, tremor, confusion, or loss of consciousness), seek urgent medical attention.

Not sure if this is normal? Chat with one of our pharmacists →

Lifestyle modification remains the cornerstone of management and is strongly supported by NICE guidance (PH38). Evidence consistently shows that even modest improvements in diet and physical activity can significantly reduce insulin resistance and lower fasting insulin levels. Key recommendations include:

• Dietary changes: Reducing refined carbohydrates and ultra-processed foods, increasing dietary fibre, and adopting a balanced diet in line with the NHS Eatwell Guide. Some individuals benefit from lower-carbohydrate approaches, though these should be discussed with a healthcare professional before making significant changes.

• Physical activity: The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week (or 75 minutes of vigorous-intensity activity, or an equivalent combination), alongside muscle-strengthening activities on two or more days. Resistance exercise is particularly effective at improving insulin sensitivity in skeletal muscle.

• Weight management: Even a 5–10% reduction in body weight can meaningfully improve insulin sensitivity. NHS Tier 2 (community-based) and Tier 3 (specialist multidisciplinary) weight management services may be available depending on your BMI and clinical need; eligibility thresholds vary locally. Ethnicity-adjusted BMI thresholds apply for South Asian, Chinese, and other at-risk groups (typically action thresholds are lower by approximately 2.5 kg/m²). Discuss referral options with your GP.

For individuals with PCOS, NICE guidance (NG88) supports the use of metformin to improve insulin sensitivity, particularly where lifestyle measures alone are insufficient. Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. It is not licensed specifically for insulin resistance without diabetes, and its use in PCOS is therefore off-label in the UK; this should be discussed with your clinician, including any implications if you are planning a pregnancy. For full prescribing information, refer to the UK Summary of Product Characteristics (SmPC) for metformin. If you experience any suspected side effects from metformin or any other medicine, you can report these via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk).

The NHS Diabetes Prevention Programme (NHS DPP) may be accessible to those identified as being at high risk of type 2 diabetes. Referral is typically based on HbA1c or fasting glucose thresholds, so those with a normal HbA1c but raised insulin may not yet qualify. This is another reason why early GP engagement is valuable — to ensure appropriate monitoring, timely repeat testing (for example, annual fasting glucose or HbA1c in line with NICE PH38 and NG88 risk-based review), and referral as the clinical picture evolves.

Frequently Asked Questions